Digene HPV Genotyping RH Test RUO: Comparative evaluation with INNO-LiPA HPV Genotyping Extra Test for detection of 18 high-risk and probable high-risk human papillomavirus genotypes

BackgroundStandardized and validated methods for the specific detection and identification of a spectrum of high-risk (hr) HPV genotypes will be necessary if HPV genotyping gains an important role in the clinical management of HPV-related precancerous lesions and cancers.ObjectivesThe first comparative evaluation of novel HPV genotyping Digene HPV Genotyping RH Test RUO (Qiagen, Hilden, Germany) with standard INNO-LiPA HPV Genotyping Extra CE assay (Innogenetics, Gent, Belgium).Study designSeventy hr-HPV positive samples were tested in parallel with both genotyping assays. The results were interpreted taking into account 15 hr-HPV and 3 probable hr-HPV genotypes that can be identified by both assays (assay-common genotypes).ResultsConcordant results (a complete match of assay-common genotypes or negative using both assays) and compatible results (at least one genotype in common) were obtained in 42 (60.0%) and 28 (40.0%) samples, respectively. No discordant results for assay-common genotypes were obtained. Of 42 samples with compatible results, the presence of at least one assay-common genotype was detected in 37 samples, while no HPV was detected in two samples by both assays and only a single low-risk HPV was detected by INNO-LiPA in three samples.ConclusionsA novel Digene test is suitable for the detection of hr-HPV genotypes in clinical samples and it provides comparable results to the well established INNO-LiPA assay. Although INNO-LiPA identified significantly more samples with multiple HPV genotypes than the Digene test, the clinical benefit of such a difference is at present unclear.     

The role of Chlamydia trachomatis in prostatitis syndrome--our experience in diagnosis and treatment

Since the beginning of 1999, over 1500 patients with symptoms of chronic prostatitis were examined at Dr. Fran Mihaljevi? University Hospital for Infectious Diseases in Zagreb. In almost all of these patients urethral swabs and quantitative segmented bacteriologic cultures and microscopy of expressed prostatic secretion (EPS) or voided bladder urine3 (VB3) were performed as described by Meares and Stamey. Urethral swabs, EPS or VB3 were examined for the presence of Chlamydia (C.) trachomatis by McCoy culture and Lugol stain or by immunofluorescent typing with monoclonal antibodies. In the majority of patients C. trachomatis was demonstrated in parallel in EPS or VB3 by DNA/RNA hybridization method. Normal white blood cell count viewed per high power field<10 was found in 362 (68%) of 536 patients with symptoms of chronic prostatitis and C. trachomatis detected in EPS or VB3. These findings additionally suggest that C. trachomatis can be suspected as a causative pathogen in all categories of chronic prostatitis syndrome. Furthermore, this paper summarizes the results of five previously published clinical studies on the efficacy and tolerability of various treatment schemes for chronic chlamydial prostatitis, conducted from the beginning of 1999 until the end of 2003.     

全固态炎痛静电极与底液介电常数对电极性能的影响

全固态结构的杂多酸型炎痛静电极具有良好的电极性能,线性响应范围下限可达1.5×10^-6mol/L,可用于生物体液及微体积中微克量级炎痛静的测定。发现;在不同介电常数的乙醇—水混合底液中,杂多酸型(磷钨酸、硅钨酸)电极的响应性能与二环己基萘磺酸、二苦胺、四苯硼、四碘合铋酸或苦味酸型电极不同,并不因底液介电常数之降低而显著改变其斜率。     

阳、阴离子型药物电位滴定通用电极的比较研究

磷钨酸十六烷基三辛基铵电极可用于多种阳离子型及阴离子型药物的电位滴定,分别用四苯硼钠及硫酸作滴定剂,电位突跃可达150～400 mV,最低测定浓度可达10^-5mol/L左右,经过短时转化,即可改用于不同药物的滴定。季磷、季钟盐型电极或其它阴离子型电极性能较差。电活性物显示烃基加重效应。电极结构无显著影响。表面活性剂苯扎溴铵可加速活化。     

Short report: octreotide in the treatment of external pancreatic fistulas

The efficacy of the long-lasting somatostatin analogue, octreotide, in the treatment of high-output pancreatic fistulas was investigated in this prospective, open study. Sixteen patients with post-operative pancreatic fistulas were treated with subcutaneous injections of octreotide 0.1 mg b.d. The output of the fistulas before the somatostatin therapy ranged between 190 and 5 70 ml/day. The therapy was begun on average 17 days following the appearance of the fistula (range 4 to 35 days). The decrease in volume one day after initiation of therapy ranged from 26% to 69%. By the third day of treatment the fistula volume decreased to 0–45% of the initial output. The treatment resulted in the closure of 14 of the 16 fistulas; the time to closure ranging from 3 to 15 days. The results suggest that octreotide is a useful adjuvant agent in the treatment of an external pancreatic fistula.     

在脉冲电流作用下胰岛素经皮吸收对糖尿病大鼠血糖的影响

实验结果表明,在一定范围内糖尿病大鼠血糖下降的幅度与脉冲电流强度、频率及治疗时间成正比,但当脉冲电流强度超过0.8mA/cm2,频率超过3000Hz时,糖尿病大鼠血糖下降的幅度不再继续增加,即应用较小的电流强度及脉冲频率就能有效地促进胰岛素透皮吸收。同时脉冲电流的占空比为1:l时,糖尿病大鼠血糖下降的幅度最大。为使糖尿病大鼠血糖下降的幅度基本相当,皮下注射与经皮吸收方式给药所用胰岛素的剂量约为1:16。     

补肾中药靶向经穴给药对骨质疏松患者的归经调节

目的:通过临床实验观察补肾方药靶向经穴位给药治疗骨质疏松症的疗效,分析靶向给药与药物归经的相关性。方法:①观察对象:选择2004-08/2006-12河北医科大学骨质疏松专科门诊和石家庄市桥东区医院门诊骨质疏松患者180例(患者知情同意,并经单位伦理委员会批准)。②实验分组:采用随机数字表法将180例患者分为6组:补肾方药口服组,外贴肾经组,外贴膀胱经组,依普拉封组,骨疏康组,非经非穴位组,每组30例,平均年龄(60.5±6.0)岁,平均病程(6.32±2.03)年。6组一般资料差异无显著性(P>0.05),具有可比性。补肾方药由地黄、淫羊藿、山药、丹参、骨碎补、独活等药物组成,每5丸含原药材3g;抗骨松贴剂:由地黄、淫羊藿、山药、丹参、骨碎补、独活等药物组成);依普拉封为正大青春宝药业有限公司产品;骨疏康颗粒由熟地黄、淫羊藿、黄芪、丹参、骨碎补、木耳、黄瓜子组成。③实验干预:补肾方药口服组:口服补肾方药10丸/次,3次/d,连续服用6个月。外贴肾经穴位组:选择足少阴肾经原穴太溪和络穴大钟;外贴膀胱经穴位组:选择足太阳膀胱经背部肾俞穴和络穴飞扬;外贴非经非穴位组:选择大腿外侧和后背部较广阔没有经络循行的区域;外贴组每个穴位贴2g生药量,每2天1次,左右交替进行。依普拉封组:口服依普拉封200mg/次,3次/d。骨疏康组:口服骨疏康颗粒10g/次,2次/d,各组均以6个月为1疗程,用药期间不进行任何其他中西医抗骨质疏松治疗。④实验评估:比较6组的骨痛症状与骨密度、血清Ca、P、碱性磷酸酶、尿羟脯氨酸,甲状旁腺素、降钙素、雌二醇、睾酮等指标的变化情况。进行综合疗效评价,评估标准分为显效、有效、无效。结果:180例患者全部进入结果分析。①补肾方药口服组、外贴肾经组、外贴膀胱经组、依普拉封组、骨疏康组治疗后,升高骨密度、雌二醇、睾酮、降钙素;降低甲状旁腺素;总有效率分别为90.0%,83.33%,83.33%,83.33%,83.33%。②非经非穴位组治疗后,骨密度、雌二醇、睾酮、降钙素、甲状旁腺素与治疗前比较差异无显著性(P>0.05);总有效率为46.67%。结论:靶向经穴给药可明显提高补肾方药的归经调节作用,至少在骨和性腺两个靶点起作用。